Risk-based decisions on when to investigate deeper, escalate, or close — recognizing when repeat deviations, OOS results, and complaints signal a systemic problem, and why RCA so often fails to hold on repeat.
Includes live access & recording
Repeat deviations, repeat OOS results, and repeat market complaints all raise the same uncomfortable question in different forms. Is this genuinely the same problem returning, a similar event with a different cause, or the first visible sign of something systemic? Does recurrence mean the previous investigation was inadequate? Was the root cause wrong? Did the CAPA fail, or was it never actually capable of preventing recurrence in the first place?
And when several individually minor events across deviations, OOS, and complaints begin pointing in the same direction, at what point does their combined significance demand a different response?
This 2-hour webinar examines these decisions alongside two connected operational realities: growing investigation and CAPA backlogs, and the recurring problem of root cause analysis (RCA) that looks complete on paper but fails to prevent the next occurrence.
Every open record cannot receive unlimited investigation, yet closure simply to meet aging targets can leave important questions, and weak CAPAs unresolved. Risk, recurrence, product and process impact, previous history, strength of evidence, and effectiveness of earlier actions all influence how much investigation is justified and where limited resources should be concentrated.
The session brings these factors together around the decisions that matter in practice: when to keep digging, when to widen the investigation, when an issue needs escalation, whether CAPA is actually warranted, why RCA so often fails to hold up on repeat, and when the available evidence is sufficient to close.
It also examines how apparently separate events across deviations, OOS, and complaints can change significance when viewed collectively, how to build and use Quality Risk Management (QRM) more meaningfully into CAPA decision-making rather than as a documentation formality, and how backlog pressure can be managed without allowing age or closure metrics to drive the wrong decisions.
By the end of this session, participants will be equipped to make defensible, risk-based investigation and CAPA decisions when problems recur.
Identify when recurrence changes the risk profile of a deviation, OOS, or complaint and calls for deeper investigation.
Recognize when multiple individually minor events across deviations, OOS, and complaints point to a systemic problem.
Determine how far an investigation should go, including expanding scope and reopening previous findings.
Recognize common RCA failure patterns and challenge previous root-cause conclusions when a problem returns.
Determine whether CAPA is actually required and whether it addresses the real cause or just the latest symptom.
Strengthen CAPA effectiveness through Quality Risk Management and size the response to the actual risk.
Apply risk-based rather than age-based prioritization to CAPA backlogs and aging investigations.
Decide how much evidence is enough to close an investigation or CAPA, including effectiveness checks themselves.
Focused areas that will strengthen how your organization handles recurring quality events and their backlogs.
Distinguish the same problem returning from a similar event with a different cause, and know when recurrence changes the risk.
Recognize when multiple events across deviations, OOS, and complaints combine into a systemic signal that demands a different response.
Learn the common failure patterns behind root cause analysis that looks complete on paper but doesn't prevent the next occurrence.
Prioritize investigation and CAPA backlogs by risk rather than age, without letting closure metrics drive the wrong decisions.
A comprehensive look at the decisions behind repeat deviations, OOS results, RCA effectiveness, and CAPA backlog management.
Professionals across quality, regulatory, manufacturing, and technical functions responsible for investigations, RCA, and CAPA decisions.
Quality Assurance Departments
Quality Control Departments
Regulatory Affairs Departments
Manufacturing Departments
Operations Departments
Validation and Engineering Departments
Technical Operations Teams
Site and Quality Management
Repeat deviations, repeat OOS results, and repeat market complaints all raise the same uncomfortable question in different forms: is this genuinely the same problem returning, a similar event with a different cause, or the first visible sign of something systemic? Recurrence forces organizations to confront whether the previous investigation was inadequate, whether the root cause was wrong, or whether the CAPA failed — or was never actually capable of preventing recurrence in the first place.
Every open record cannot receive unlimited investigation, yet closure simply to meet aging targets can leave important questions, and weak CAPAs, unresolved. Risk, recurrence, product and process impact, previous history, strength of evidence, and effectiveness of earlier actions all influence how much investigation is justified and where limited resources should be concentrated.
A risk-based approach brings these factors together around the decisions that matter in practice — when to keep digging, when to widen the investigation, when an issue needs escalation, whether CAPA is actually warranted, why RCA so often fails to hold up on repeat, and when the available evidence is sufficient to close — while building Quality Risk Management more meaningfully into CAPA decision-making rather than treating it as a documentation formality.
G. Sundar is a quality practitioner with vast 35 years' experience in the field of Quality Assurance, Quality Control, Bioequivalence and Pharmaceutical Regulations. His quality management experience covers the implementation of Quality tools in bulk drugs, formulation companies and CRO. He is an expert in Total Quality Systems as per GLP, GDP and as per EMEA, USFDA, MHRA and MCC, TGA, ANVISA, Japan guidelines.
He has conducted more than 200 GMP/GLP audits including Q10 & Q11 implementation, 50 Formulation Contract Manufacturing Units (all types of formulations), 10 Contract Research and Analytical laboratories, and 10 Clinical research CROs. He has also conducted 1000-plus trainings across Asia, US, EU, Middle East and South-East Asia. Mr. Sundar Ganesan is the Director and Senior Consultant at PharmQA Compliance Services.
Don't miss this essential training on risk-based decisions for repeat deviations, OOS results, RCA, and CAPA effectiveness. Secure your spot now.